ISK9_HUMAN
ID ISK9_HUMAN Reviewed; 86 AA.
AC Q5DT21; B2RPN9;
DT 20-MAY-2008, integrated into UniProtKB/Swiss-Prot.
DT 29-MAR-2005, sequence version 1.
DT 03-AUG-2022, entry version 105.
DE RecName: Full=Serine protease inhibitor Kazal-type 9;
DE AltName: Full=Lymphoepithelial Kazal-type-related inhibitor 2;
DE Flags: Precursor;
GN Name=SPINK9; Synonyms=LEKTI2;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 20-33, IDENTIFICATION BY
RP MASS SPECTROMETRY, FUNCTION, SUBUNIT, TISSUE SPECIFICITY, AND INTERACTION
RP WITH KLK5 AND KLK8.
RX PubMed=19194479; DOI=10.1038/jid.2008.448;
RA Brattsand M., Stefansson K., Hubiche T., Nilsson S.K., Egelrud T.;
RT "SPINK9: a selective, skin-specific Kazal-type serine protease inhibitor.";
RL J. Invest. Dermatol. 129:1656-1665(2009).
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 26-50, IDENTIFICATION BY
RP MASS SPECTROMETRY, FUNCTION, AND TISSUE SPECIFICITY.
RC TISSUE=Skin;
RX PubMed=19190773; DOI=10.1371/journal.pone.0004372;
RA Meyer-Hoffert U., Wu Z., Schroeder J.M.;
RT "Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin
RT as a kallikrein-related peptidase 5-specific protease inhibitor.";
RL PLoS ONE 4:E4372-E4372(2009).
RN [3]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
CC -!- FUNCTION: Serine protease inhibitor which specifically inhibits KLK5.
CC May contribute to the regulation of the desquamation process in skin by
CC inhibiting KLK5. {ECO:0000269|PubMed:19190773,
CC ECO:0000269|PubMed:19194479}.
CC -!- SUBUNIT: Dimer. Interacts with KLK5 and KLK8.
CC {ECO:0000269|PubMed:19194479}.
CC -!- INTERACTION:
CC Q5DT21; O43765: SGTA; NbExp=3; IntAct=EBI-13119580, EBI-347996;
CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000305}.
CC -!- TISSUE SPECIFICITY: Skin. Highly expressed at sites of hyperkeratosis.
CC Also detected in thymus, tonsils, testis, pancreas, liver, placenta and
CC brain. Expressed at stratum granulosum and stratum corneum at palmar
CC and plantar sites (at protein level). {ECO:0000269|PubMed:19190773,
CC ECO:0000269|PubMed:19194479}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AY396740; AAR91618.1; -; mRNA.
DR EMBL; BC137530; AAI37531.1; -; mRNA.
DR EMBL; BC137531; AAI37532.1; -; mRNA.
DR CCDS; CCDS34269.1; -.
DR RefSeq; NP_001035523.1; NM_001040433.1.
DR AlphaFoldDB; Q5DT21; -.
DR SMR; Q5DT21; -.
DR BioGRID; 568744; 2.
DR IntAct; Q5DT21; 1.
DR STRING; 9606.ENSP00000367139; -.
DR MEROPS; I01.054; -.
DR BioMuta; SPINK9; -.
DR DMDM; 74707721; -.
DR MassIVE; Q5DT21; -.
DR PaxDb; Q5DT21; -.
DR PeptideAtlas; Q5DT21; -.
DR PRIDE; Q5DT21; -.
DR ProteomicsDB; 62751; -.
DR Antibodypedia; 49040; 49 antibodies from 14 providers.
DR DNASU; 643394; -.
DR Ensembl; ENST00000377906.2; ENSP00000367139.1; ENSG00000204909.8.
DR GeneID; 643394; -.
DR KEGG; hsa:643394; -.
DR MANE-Select; ENST00000377906.2; ENSP00000367139.1; NM_001040433.2; NP_001035523.1.
DR UCSC; uc003lpe.1; human.
DR CTD; 643394; -.
DR GeneCards; SPINK9; -.
DR HGNC; HGNC:32951; SPINK9.
DR HPA; ENSG00000204909; Tissue enhanced (brain).
DR MIM; 613511; gene.
DR neXtProt; NX_Q5DT21; -.
DR OpenTargets; ENSG00000204909; -.
DR PharmGKB; PA162404560; -.
DR VEuPathDB; HostDB:ENSG00000204909; -.
DR eggNOG; KOG3649; Eukaryota.
DR GeneTree; ENSGT00530000064312; -.
DR HOGENOM; CLU_169765_4_0_1; -.
DR InParanoid; Q5DT21; -.
DR OMA; CHEIYAP; -.
DR PhylomeDB; Q5DT21; -.
DR PathwayCommons; Q5DT21; -.
DR Reactome; R-HSA-6809371; Formation of the cornified envelope.
DR SignaLink; Q5DT21; -.
DR BioGRID-ORCS; 643394; 12 hits in 1033 CRISPR screens.
DR GenomeRNAi; 643394; -.
DR Pharos; Q5DT21; Tbio.
DR PRO; PR:Q5DT21; -.
DR Proteomes; UP000005640; Chromosome 5.
DR RNAct; Q5DT21; protein.
DR Bgee; ENSG00000204909; Expressed in corpus callosum and 90 other tissues.
DR ExpressionAtlas; Q5DT21; baseline and differential.
DR GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; IDA:UniProtKB.
DR InterPro; IPR002350; Kazal_dom.
DR InterPro; IPR036058; Kazal_dom_sf.
DR InterPro; IPR001239; Prot_inh_Kazal-m.
DR Pfam; PF00050; Kazal_1; 1.
DR PRINTS; PR00290; KAZALINHBTR.
DR SMART; SM00280; KAZAL; 1.
DR SUPFAM; SSF100895; SSF100895; 1.
DR PROSITE; PS00282; KAZAL_1; 1.
DR PROSITE; PS51465; KAZAL_2; 1.
PE 1: Evidence at protein level;
KW Direct protein sequencing; Disulfide bond; Protease inhibitor;
KW Reference proteome; Secreted; Serine protease inhibitor; Signal.
FT SIGNAL 1..19
FT /evidence="ECO:0000269|PubMed:19194479"
FT CHAIN 20..86
FT /note="Serine protease inhibitor Kazal-type 9"
FT /id="PRO_0000333808"
FT DOMAIN 26..86
FT /note="Kazal-like"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT SITE 48..49
FT /note="Reactive bond"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT DISULFID 32..68
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT DISULFID 46..65
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT DISULFID 54..86
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT CONFLICT 27
FT /note="K -> Q (in Ref. 1; AA sequence)"
FT /evidence="ECO:0000305"
SQ SEQUENCE 86 AA; 9756 MW; D6C7598B95DAAC33 CRC64;
MRATAIVLLL ALTLATMFSI ECAKQTKQMV DCSHYKKLPP GQQRFCHHMY DPICGSDGKT
YKNDCFFCSK VKKTDGTLKF VHFGKC
